The Shifting Face of Liver Cancer: Why Women Are Now at Greater Risk
A comprehensive analysis of U.S. mortality data from 1999 to 2023 reveals a critical divergence in liver cancer trends between men and women. While male mortality for hepatocellular carcinoma (HCC) has plateaued and begun to decline, female mortality continues to rise. This shift is driven by two key factors: a change in the underlying causes of HCC and a dramatic increase in intrahepatic cholangiocarcinoma (iCCA). The era of direct-acting antivirals has successfully reduced HCV-related HCC deaths. However, this has been offset by a steady climb in HCC linked to metabolic dysfunction-associated steatotic liver disease (MASLD), now the leading reported etiology. Concurrently, iCCA mortality has surged, particularly among women and younger adults, accounting for 44% of female liver cancer deaths by 2023.
Why it might matter to you: For gastroenterologists and hepatologists, these evolving epidemiological patterns necessitate a recalibration of screening and surveillance strategies. The rising burden of MASLD-related HCC and iCCA, especially in women, highlights gaps in current risk stratification models that were historically built around viral hepatitis and alcoholic liver disease. This data underscores the need for increased clinical vigilance for liver cancer in female patients with metabolic risk factors and may inform discussions about expanding surveillance criteria to capture this changing at-risk population.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
